Abstract
Patients with K-RAS wild-type (WT) metastatic colorectal cancer (mCRC) are currently considered the optimal candidates for upfront treatment with combinations of chemotherapy and EGFR inhibitors. These combinations significantly extend overall survival (OS) compared to chemotherapy alone. However, a proportion of patients would not achieve this goal. This study has investigated the ability of an artificial intelligence-based analytical tool that, based on patients clinical parameters, can identify those on which the addition of EGFR inhibitors to initial chemotherapy is likely to be effective.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
